



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2016





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

July 2016

N = 7072



Health Authority	Male	Female	All
FRASER	1337	383	1720
INTERIOR	363	96	459
NORTHERN	134	74	208
VANCOUVER COASTAL	3364	449	3813
VANCOUVER ISLAND	688	156	844
	<b>5886</b>	<b>1158</b>	<b>7044</b>
		<b>Unknown/not stated:</b>	<b>28</b>
		<b>Total:</b>	<b>7072</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2011 - July 2016)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2011 - July 2016)






### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (July 2011 - July 2016)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (July 2011 - July 2016)






1.6 Percent Distribution of Active Participants by CD4 Count  
(July 2011 - July 2016)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2011 - July 2016)





### 1.8 Active and Inactive Participants (July 2011 - July 2016)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2011 - July 2016)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2011 - July 2016)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(July 2011 - July 2016)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2011 - July 2016)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(July 2011 - July 2016)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2011 - July 2016)






**1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT**

(July 2011 - July 2016)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2011 - July 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT (July 2011 - July 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (July 2011 - July 2016)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (July 2011 - July 2016)






### 1.20 Cumulative Resistance Testing Results by Resistance Category (July 2011 - July 2016)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2011 - July 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	4	0	4	4	900	4	<40	3
1988	24	7	0	7	7	490	7	<40	3
1989	23	53	2	55	48	505	54	<40	3
1990	22	61	1	62	58	540	61	<40	3
1991	22	38	3	41	34	530	38	<40	3
1992	22	70	6	76	61	590	71	<40	3
1993	21	144	14	158	143	550	155	<40	3
1994	20	96	14	110	95	560	104	<40	3
1995	20	129	23	152	125	540	138	<40	3
1996	18	368	60	428	378	630	420	<40	3
1997	16	308	40	348	315	620	337	<40	3
1998	15	221	45	266	228	580	251	<40	3
1999	15	182	40	222	196	560	212	<40	3
2000	15	135	39	174	154	560	170	<40	3
2001	15	130	34	164	140	590	151	<40	3
2002	14	141	31	172	146	600	163	<40	3
2003	13	172	31	203	174	600	192	<40	3
2004	12	179	41	220	194	590	209	<40	3
2005	11	207	48	255	216	610	240	<40	3
2006	10	212	46	258	217	590	241	<40	3
2007	9	277	56	333	284	600	318	<40	3
2008	8	312	73	385	330	610	367	<40	3
2009	7	350	76	426	367	650	413	<40	3
2010	6	312	74	386	339	630	370	<40	3
2011	5	364	79	443	377	670	415	<40	3
2012	4	299	65	364	314	710	346	<40	3
2013	3	286	70	356	294	650	343	<40	3
2014	2	319	59	378	312	680	360	<40	3
2015	1	346	56	402	344	610	386	<40	3
2016	0	171	34	205	194	515	203	<40	3
<b>Total:</b>		<b>5893</b>	<b>1160</b>	<b>7053</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6739	760	2430	<40	2189	580
FEB-2015	6787	754	1976	<40	1779	580
MAR-2015	6834	748	2173	<40	1973	570
APR-2015	6845	739	2150	<40	1971	580
MAY-2015	6882	740	2032	<40	1842	560
JUN-2015	6898	740	2254	<40	2044	580
JUL-2015	6925	739	2037	<40	1853	580
AUG-2015	6922	752	2075	<40	1831	580
SEP-2015	6923	749	2265	<40	2059	580
OCT-2015	6957	740	2100	<40	1878	590
NOV-2015	7009	722	2064	<40	1874	580
DEC-2015	6991	725	2015	<40	1829	600
JAN-2016	6978	735	2264	<40	2017	590
FEB-2016	6996	735	2066	<40	1861	590
MAR-2016	7006	736	2157	<40	1953	590
APR-2016	7027	733	2054	<40	1850	590
MAY-2016	7057	743	2075	<40	1848	590
JUN-2016	7079	738	2182	<40	1924	610
JUL-2016	7072	749	1950	<40	1683	610

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1513	2042	104	1325	89	340
FEB-2015	1497	2111	103	75	89	380
MAR-2015	1469	2260	101	56	95	410
APR-2015	1475	2244	83	2239	73	460
MAY-2015	1459	2353	73	148	65	380
JUN-2015	1476	2271	96	106	92	420
JUL-2015	1469	2336	71	598	60	380
AUG-2015	1480	2303	82	2341	77	440
SEP-2015	1504	2231	91	128	85	360
OCT-2015	1486	2347	81	<40	70	405
NOV-2015	1462	2458	85	169	78	400
DEC-2015	1498	2318	79	344	64	330
JAN-2016	1509	2304	114	<40	102	470
FEB-2016	1502	2363	80	751	71	380
MAR-2016	1505	2342	85	130	80	445
APR-2016	1508	2342	86	<50	72	355
MAY-2016	1493	2409	74	<40	64	350
JUN-2016	1501	2428	69	56	53	510
JUL-2016	1528	2343	82	74	73	430

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6706	1513	13	24	149	188	-35	11954
FEB-2015	6756	1497	7	36	187	163	50	12006
MAR-2015	6809	1469	7	29	177	144	53	12046
APR-2015	6808	1475	15	28	168	172	-1	12082
MAY-2015	6847	1459	9	33	171	150	39	12123
JUN-2015	6870	1476	5	36	153	159	23	12170
JUL-2015	6906	1469	5	25	167	149	36	12208
AUG-2015	6903	1480	7	19	145	157	-3	12238
SEP-2015	6899	1504	9	32	157	180	-4	12279
OCT-2015	6927	1486	14	24	171	147	28	12316
NOV-2015	6979	1462	9	29	183	149	52	12357
DEC-2015	6958	1498	11	22	153	181	-21	12390
JAN-2016	6949	1509	9	16	154	167	-9	12411
FEB-2016	6970	1502	5	18	176	162	21	12439
MAR-2016	6983	1505	8	25	170	170	13	12473
APR-2016	7007	1508	6	21	167	157	24	12508
MAY-2016	7039	1493	7	24	159	143	32	12539
JUN-2016	7059	1501	11	35	160	162	20	12582
JUL-2016	7053	1528	8	26	135	156	-6	12615

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	<b>6742</b>	0.71%	91.66%	6.53%	1.10%	<b>100.00%</b>
FEB-2015	49	6219	451	73	<b>6792</b>	0.72%	91.56%	6.64%	1.07%	<b>100.00%</b>
MAR-2015	47	6287	436	67	<b>6837</b>	0.69%	91.96%	6.38%	0.98%	<b>100.00%</b>
APR-2015	47	6296	435	67	<b>6845</b>	0.69%	91.98%	6.36%	0.98%	<b>100.00%</b>
MAY-2015	49	6334	431	68	<b>6882</b>	0.71%	92.04%	6.26%	0.99%	<b>100.00%</b>
JUN-2015	51	6329	446	72	<b>6898</b>	0.74%	91.75%	6.47%	1.04%	<b>100.00%</b>
JUL-2015	46	6359	453	67	<b>6925</b>	0.66%	91.83%	6.54%	0.97%	<b>100.00%</b>
AUG-2015	48	6360	444	70	<b>6922</b>	0.69%	91.88%	6.41%	1.01%	<b>100.00%</b>
SEP-2015	48	6372	439	64	<b>6923</b>	0.69%	92.04%	6.34%	0.92%	<b>100.00%</b>
OCT-2015	52	6399	442	64	<b>6957</b>	0.75%	91.98%	6.35%	0.92%	<b>100.00%</b>
NOV-2015	55	6442	445	67	<b>7009</b>	0.78%	91.91%	6.35%	0.96%	<b>100.00%</b>
DEC-2015	52	6429	448	62	<b>6991</b>	0.74%	91.96%	6.41%	0.89%	<b>100.00%</b>
JAN-2016	54	6415	448	61	<b>6978</b>	0.77%	91.93%	6.42%	0.87%	<b>100.00%</b>
FEB-2016	54	6446	437	59	<b>6996</b>	0.77%	92.14%	6.25%	0.84%	<b>100.00%</b>
MAR-2016	53	6454	438	61	<b>7006</b>	0.76%	92.12%	6.25%	0.87%	<b>100.00%</b>
APR-2016	53	6475	442	57	<b>7027</b>	0.75%	92.14%	6.29%	0.81%	<b>100.00%</b>
MAY-2016	56	6507	439	55	<b>7057</b>	0.79%	92.21%	6.22%	0.78%	<b>100.00%</b>
JUN-2016	59	6515	448	57	<b>7079</b>	0.83%	92.03%	6.33%	0.81%	<b>100.00%</b>
JUL-2016	57	6515	443	57	<b>7072</b>	0.81%	92.12%	6.26%	0.81%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		emtricitabine		tenofovir <TAF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2583 40%	10 29%	2220 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3846 59%	0 0%	0 0%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3878 59%	0 0%	0 0%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3913 59%	0 0%	0 0%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3911 59%	0 0%	0 0%
MAY-2015	8 20%	2638 40%	7 18%	2280 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3923 59%	0 0%	0 0%
JUN-2015	10 21%	2633 39%	10 21%	2287 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3942 59%	0 0%	0 0%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3945 59%	0 0%	0 0%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3941 59%	0 0%	0 0%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3911 58%	0 0%	0 0%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3901 58%	0 0%	0 0%
NOV-2015	17 41%	2787 41%	15 37%	2442 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3911 58%	0 0%	0 0%
DEC-2015	5 15%	2795 41%	5 15%	2456 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	28 85%	3886 57%	0 0%	0 0%
JAN-2016	4 19%	2821 42%	4 19%	2488 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3856 57%	0 0%	0 0%
FEB-2016	10 36%	2855 42%	9 32%	2523 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3834 57%	0 0%	0 0%
MAR-2016	9 26%	2880 42%	7 21%	2545 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3817 56%	0 0%	0 0%
APR-2016	12 34%	2897 43%	9 26%	2571 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	23 66%	3822 56%	0 0%	5 0%
MAY-2016	8 26%	2900 43%	8 26%	2584 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	23 74%	3843 56%	0 0%	6 0%
JUN-2016	11 26%	2930 43%	11 26%	2608 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	32 74%	3840 56%	1 2%	8 0%
JUL-2016	9 27%	2908 43%	9 27%	2588 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	24 73%	3844 56%	0 0%	8 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	tenofovir <TDF>			
	Initial		All	
JAN-2015	25	71%	4210	64%
FEB-2015	44	85%	4241	64%
MAR-2015	30	75%	4269	64%
APR-2015	24	69%	4267	64%
MAY-2015	33	83%	4277	64%
JUN-2015	37	79%	4293	64%
JUL-2015	34	89%	4295	64%
AUG-2015	18	60%	4281	64%
SEP-2015	24	59%	4251	63%
OCT-2015	27	73%	4239	63%
NOV-2015	25	61%	4243	63%
DEC-2015	28	85%	4211	62%
JAN-2016	17	81%	4173	62%
FEB-2016	18	64%	4141	61%
MAR-2016	26	76%	4120	61%
APR-2016	23	66%	4114	61%
MAY-2016	23	74%	4129	61%
JUN-2016	31	72%	4129	60%
JUL-2016	24	73%	4128	60%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2029 60%	6 50%	930 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2029 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	970 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 1%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	988 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2000 59%	6 38%	1018 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1966 58%	10 56%	1037 31%	0 0%	358 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1958 58%	11 79%	1050 31%	1 7%	351 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1054 31%	3 27%	345 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1912 58%	11 69%	1061 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1087 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1876 56%	9 56%	1107 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1839 56%	8 67%	1119 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1823 55%	5 45%	1131 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1794 55%	6 46%	1160 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1773 55%	11 69%	1174 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1749 54%	14 93%	1205 37%	0 0%	294 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1733 53%	10 83%	1224 38%	0 0%	283 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1714 53%	12 80%	1241 38%	0 0%	284 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	4 27%	1697 53%	11 73%	1245 39%	0 0%	274 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1083 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1074 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	3 100%	1057 43%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1035 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	260 11%
MAR-2016	2 50%	997 41%	0 0%	307 13%	1 25%	854 35%	1 25%	260 11%
APR-2016	3 33%	991 41%	1 11%	308 13%	3 33%	845 35%	2 22%	261 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	262 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	840 35%	2 33%	261 11%
JUL-2016	1 25%	970 41%	1 25%	299 13%	2 50%	837 35%	0 0%	258 11%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	540 30%	4 22%	348 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	575 31%	8 33%	354 19%	0 0%	73 4%	2 8%	879 48%	0 0%	1 0%
MAR-2015	9 50%	599 32%	5 28%	367 20%	0 0%	69 4%	4 22%	868 47%	0 0%	2 0%
APR-2015	7 50%	627 33%	4 29%	373 20%	2 14%	67 4%	1 7%	861 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	380 20%	1 6%	70 4%	2 12%	863 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	394 20%	0 0%	72 4%	4 15%	875 44%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	782 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	849 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	889 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	438 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	988 43%	10 45%	445 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1021 44%	4 36%	461 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1063 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1117 46%	2 11%	483 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1157 47%	4 22%	493 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1186 47%	4 24%	495 20%	0 0%	60 2%	0 0%	799 32%	0 0%	1 0%
JUN-2016	16 62%	1219 48%	9 35%	507 20%	0 0%	58 2%	1 4%	791 31%	0 0%	1 0%
JUL-2016	14 70%	1252 49%	5 25%	521 20%	0 0%	57 2%	1 5%	785 30%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2388	34.89	2095	30.61	1237	18.07	184	2.69	67	0.98	874	12.77
MAY-2015	2392	34.76	2094	30.43	1274	18.51	179	2.60	68	0.99	875	12.71
JUN-2015	2363	34.26	2078	30.12	1321	19.15	172	2.49	72	1.04	892	12.93
JUL-2015	2370	34.22	2068	29.86	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2365	34.17	2044	29.53	1382	19.97	168	2.43	70	1.01	893	12.90
SEP-2015	2323	33.55	2032	29.35	1446	20.89	168	2.43	64	0.92	890	12.86
OCT-2015	2325	33.42	2005	28.82	1491	21.43	167	2.40	64	0.92	905	13.01
NOV-2015	2318	33.07	2012	28.71	1540	21.97	160	2.28	67	0.96	912	13.01
DEC-2015	2291	32.77	1983	28.37	1580	22.60	161	2.30	62	0.89	914	13.07
JAN-2016	2289	32.80	1946	27.89	1612	23.10	158	2.26	61	0.87	912	13.07
FEB-2016	2286	32.68	1926	27.53	1669	23.86	153	2.19	59	0.84	903	12.91
MAR-2016	2270	32.40	1907	27.22	1709	24.39	155	2.21	61	0.87	904	12.90
APR-2016	2250	32.02	1896	26.98	1759	25.03	154	2.19	57	0.81	911	12.96
MAY-2016	2264	32.08	1888	26.75	1785	25.29	156	2.21	55	0.78	909	12.88
JUN-2016	2265	32.00	1878	26.53	1817	25.67	151	2.13	57	0.81	911	12.87
JUL-2016	2235	31.60	1868	26.41	1852	26.19	151	2.14	57	0.81	909	12.85

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	24	4	2	3	4	9	450
NOV-2015	29	5	1	6	5	10	370
DEC-2015	22	2	3	4	5	7	370
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	25	4	3	4	8	6	380
APR-2016	21	2	1	2	2	10	600
MAY-2016	24	2	1	3	4	14	514
JUN-2016	35	5	6	6	10	8	380
JUL-2016	26	2	6	6	3	8	320

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10389	2657
FEB-2015	10435	2664
MAR-2015	10474	2673
APR-2015	10494	2685
MAY-2015	10548	2709
JUN-2015	10634	2756
JUL-2015	10703	2804
AUG-2015	10769	2860
SEP-2015	10854	2915
OCT-2015	10906	2955
NOV-2015	10969	2995
DEC-2015	11015	3022
JAN-2016	11050	3053
FEB-2016	11144	3135
MAR-2016	11205	3183
APR-2016	11251	3216
MAY-2016	11312	3265
JUN-2016	11370	3297
JUL-2016	11426	3338

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
July 2016

N = 7072

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>34</b>	<b>47</b>	<b>21</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>70</b>	<b>91</b>	<b>50</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>327</b>	<b>431</b>	<b>251</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	20	20	14
	35-49	60	68	43
	50+	97	144	80
<b>Total HSDA:</b>	<b>182</b>	<b>237</b>	<b>137</b>	
<b>Total HA:</b>		<b>613</b>	<b>806</b>	<b>459</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	51	52	*
	35-49	176	205	*
	50+	377	540	*
<b>Total HA:</b>		<b>613</b>	<b>806</b>	<b>459</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	477	639	363
Female	136	167	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	459	53	570	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	10
	5 years or more	6	5
	<5 years	11	6
	<b>Total HSDA:</b>	<b>34</b>	<b>21</b>
KOOTENAY BOUNDARY	10 years or more	36	25
	5 years or more	21	16
	<5 years	13	9
	<b>Total HSDA:</b>	<b>70</b>	<b>50</b>
OKANAGAN	10 years or more	173	124
	5 years or more	72	58
	<5 years	82	69
	<b>Total HSDA:</b>	<b>327</b>	<b>251</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	90	58
	5 years or more	44	39
	<5 years	48	40
	<b>Total HSDA:</b>	<b>182</b>	<b>137</b>
<b>Total HA:</b>		<b>613</b>	<b>459</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	316	217
	5 years or more	143	118
	<5 years	154	124
<b>Total HA:</b>		<b>613</b>	<b>459</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	52	13	22
KOOTENAY BOUNDARY	63	112	25	41
OKANAGAN	196	680	62	246
THOMPSON/CARIBOO/SHUSWAP	126	419	40	111
<b>Total:</b>	<b>421</b>	<b>1263</b>	<b>140</b>	<b>420</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	0
KOOTENAY BOUNDARY	13
OKANAGAN	40
THOMPSON/CARIBOO/SHUSWAP	39
<b>Total:</b>	<b>92</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	29	30	23
	35-49	105	114	79
	50+	180	242	144
	<b>Total HSDA:</b>		<b>321</b>	<b>393</b>
FRASER NORTH	0-19	19	19	*
	20-34	101	102	*
	35-49	351	401	*
	50+	473	737	*
	<b>Total HSDA:</b>		<b>944</b>	<b>1259</b>
FRASER SOUTH	0-19	10	10	6
	20-34	102	104	75
	35-49	353	405	288
	50+	431	638	361
	<b>Total HSDA:</b>		<b>896</b>	<b>1157</b>
<b>Total HA:</b>		<b>2161</b>	<b>2809</b>	<b>1720</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	36	36	16
	20-34	232	236	177
	35-49	809	920	631
	50+	1084	1617	896
<b>Total HA:</b>		<b>2161</b>	<b>2809</b>	<b>1720</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1642	2162	1337
Female	519	647	383

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1720	50	610	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	155	113
	5 years or more	91	78
	<5 years	75	61
	<b>Total HSDA:</b>	<b>321</b>	<b>252</b>
FRASER NORTH	10 years or more	456	335
	5 years or more	250	208
	<5 years	238	195
	<b>Total HSDA:</b>	<b>944</b>	<b>738</b>
FRASER SOUTH	10 years or more	411	324
	5 years or more	245	200
	<5 years	240	206
	<b>Total HSDA:</b>	<b>896</b>	<b>730</b>
<b>Total HA:</b>		<b>2161</b>	<b>1720</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1022	772
	5 years or more	586	486
	<5 years	553	462
<b>Total HA:</b>		<b>2161</b>	<b>1720</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	127	408	39	79
FRASER NORTH	231	1418	65	264
FRASER SOUTH	201	1188	43	337
<b>Total:</b>	<b>559</b>	<b>3014</b>	<b>147</b>	<b>680</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	179
FRASER NORTH	614
FRASER SOUTH	498
<b>Total:</b>	<b>1291</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	74
	50+	*	*	176
	<b>Total HSDA:</b>		<b>314</b>	<b>449</b>
RICHMOND	0-19	5	5	*
	20-34	25	26	*
	35-49	45	48	*
	50+	80	119	*
	<b>Total HSDA:</b>	<b>155</b>	<b>198</b>	<b>127</b>
VANCOUVER	0-19	54	57	7
	20-34	398	405	313
	35-49	1554	1792	1142
	50+	2484	4130	1954
	<b>Total HSDA:</b>	<b>4490</b>	<b>6384</b>	<b>3416</b>
<b>Total HA:</b>		<b>4959</b>	<b>7031</b>	<b>3813</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	61	64	8
	20-34	444	452	355
	35-49	1689	1944	1255
	50+	2765	4571	2195
<b>Total HA:</b>		<b>4959</b>	<b>7031</b>	<b>3813</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4356	6179	3364
Female	601	850	449

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3813	51	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	172	140
	5 years or more	58	53
	<5 years	84	77
	<b>Total HSDA:</b>	<b>314</b>	<b>270</b>
RICHMOND	10 years or more	70	54
	5 years or more	41	32
	<5 years	44	41
	<b>Total HSDA:</b>	<b>155</b>	<b>127</b>
VANCOUVER	10 years or more	2305	1656
	5 years or more	1165	905
	<5 years	1020	855
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4490</b>	<b>3416</b>
<b>Total HA:</b>	<b>4959</b>	<b>3813</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2547	1850
	5 years or more	1264	990
	<5 years	1148	973
	Never on ART	0	0
<b>Total HA:</b>		<b>4959</b>	<b>3813</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	142	368	53	91
RICHMOND	42	265	14	95
VANCOUVER	542	9917	203	5277
<b>Total:</b>	<b>726</b>	<b>10550</b>	<b>270</b>	<b>5463</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>96</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>287</b>	<b>399</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>105</b>	<b>140</b>
SOUTH VANCOUVER ISLAND	0-19	8	8	*
	20-34	51	53	*
	35-49	210	246	*
	50+	397	619	*
	<b>Total HSDA:</b>		<b>666</b>	<b>926</b>
<b>Total HA:</b>		<b>1058</b>	<b>1465</b>	<b>844</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	5
	20-34	86	91	62
	35-49	333	385	270
	50+	627	977	507
<b>Total HA:</b>		<b>1058</b>	<b>1465</b>	<b>844</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	853	1184	688
Female	205	281	156

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	844	52	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	137	108
	5 years or more	67	59
	<5 years	83	70
	<b>Total HSDA:</b>	<b>287</b>	<b>237</b>
NORTH VANCOUVER ISLAND	10 years or more	50	39
	5 years or more	26	22
	<5 years	29	21
	<b>Total HSDA:</b>	<b>105</b>	<b>82</b>
SOUTH VANCOUVER ISLAND	10 years or more	333	238
	5 years or more	170	138
	<5 years	163	149
	<b>Total HSDA:</b>	<b>666</b>	<b>525</b>
<b>Total HA:</b>		<b>1058</b>	<b>844</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	520	385
	5 years or more	263	219
	<5 years	275	240
<b>Total HA:</b>		<b>1058</b>	<b>844</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	174	743	83	201
NORTH VANCOUVER ISLAND	118	235	44	67
SOUTH VANCOUVER ISLAND	185	1553	50	523
<b>Total:</b>	<b>477</b>	<b>2531</b>	<b>177</b>	<b>791</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	93
<b>Total:</b>	<b>174</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>39</b>	<b>47</b>
NORTH WEST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>67</b>	<b>99</b>
NORTHERN INTERIOR	0-19	7	7	*
	20-34	27	29	*
	35-49	78	96	*
	50+	73	121	*
	<b>Total HSDA:</b>		<b>185</b>	<b>253</b>
<b>Total HA:</b>		<b>291</b>	<b>399</b>	<b>208</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	37	44	*
	35-49	118	150	*
	50+	127	196	*
<b>Total HA:</b>		<b>291</b>	<b>399</b>	<b>208</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	182	252	134
Female	109	147	74

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	208	48	550	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	14	7
	5 years or more	15	9
	<5 years	10	8
	<b>Total HSDA:</b>	<b>39</b>	<b>24</b>
NORTH WEST	10 years or more	18	5
	5 years or more	30	24
	<5 years	19	15
	<b>Total HSDA:</b>	<b>67</b>	<b>44</b>
NORTHERN INTERIOR	10 years or more	55	33
	5 years or more	51	45
	<5 years	79	62
	<b>Total HSDA:</b>	<b>185</b>	<b>140</b>
<b>Total HA:</b>		<b>291</b>	<b>208</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	87	45
	5 years or more	96	78
	<5 years	108	85
<b>Total HA:</b>		<b>291</b>	<b>208</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	32	58	9	11
NORTH WEST	64	143	18	25
NORTHERN INTERIOR	102	399	24	185
<b>Total:</b>	<b>198</b>	<b>600</b>	<b>51</b>	<b>221</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	18
NORTHERN INTERIOR	18
<b>Total:</b>	<b>42</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	6	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	38	*
	<b>Total HA:</b>	<b>47</b>	<b>83</b>	<b>33</b>
FRASER	FRASER EAST	30	38	26
	FRASER NORTH	56	87	42
	FRASER SOUTH	72	100	62
	<b>Total HA:</b>	<b>158</b>	<b>225</b>	<b>130</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	43	20
	RICHMOND	7	12	6
	VANCOUVER	506	791	418
	<b>Total HA:</b>	<b>536</b>	<b>846</b>	<b>444</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	53	78	43
	NORTH VANCOUVER ISLAND	12	21	10
	SOUTH VANCOUVER ISLAND	35	72	28
	<b>Total HA:</b>	<b>100</b>	<b>171</b>	<b>81</b>
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	34	57	24
	NORTHERN INTERIOR	66	98	57
	<b>Total HA:</b>	<b>109</b>	<b>166</b>	<b>88</b>
<b>Total:</b>		<b>950</b>	<b>1491</b>	<b>776</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	596	956	480
Female	354	535	296

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	776	49	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicstat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

